title: [Drug politics--economic view-point of a practitioner].
abstract: Any expenditure made in a domain leads to the diminution of the expenditures in another domain. The list of reimbursed drugs should be decided after a cost effectiveness analysis. The treatments considered too expensive in the developed countries are even more expensive for a country like Romania. The practice guidelines do not consider the economic analysis of the treatments. As soon as the results of a study are statistically significant, the specialty societies include that drug into their guidelines. A treatment is more cost effective when the risk is higher, therefore the reimbursement should have to be done function of risk, too.
authors.affiliation: L'hôpital Colentina Bucureşti, Médecine Interne II et Unité d'Epidémiologie Clinique.
authors.forename: C
authors.initials: C
authors.lastname: Băicuş
authors.forename: R
authors.initials: R
authors.lastname: Chivu
mesh_terms: D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D011307:Drug Prescriptions / Q000191:economics* / Q000592:standards; D006291:Health Policy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics; D011057:Politics; D012383:Romania
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors